Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007;9(4):289-94.
doi: 10.1080/13651820701329241.

Interferon receptor alpha/beta is associated with improved survival after adjuvant therapy in resected pancreatic cancer

Reza F Saidi  1 , Stephen G Remine, Michael J Jacobs
Affiliations

Interferon receptor alpha/beta is associated with improved survival after adjuvant therapy in resected pancreatic cancer

Reza F Saidi et al. HPB (Oxford). 2007.

Abstract

Aim: Interferons (IFNs) are known to have antiproliferative and immunoregulatory activities that are modulated through specific cell surface ligands, known as IFN-alpha, -beta, and -gamma receptors. The presence of these receptors and their impact on response to adjuvant therapy in patients with pancreatic cancer has not been determined.

Patients and methods: Slides were prepared from 46 patients with pancreatic adenocarcinoma. Immunohistochemistry (IHC) was subsequently used to determine the expression of IFN- alpha/beta receptor-chain 2 (IFN-alpha/betaR) and IFN-gamma receptor-chain 1 (IFN-gammaR). The correlation between IFN receptor expression, tumor characteristics, and the overall patient response to adjuvant therapy were determined analytically.

Results: The IHC performed for pancreatic adenocarcinoma demonstrated a high IFN-alpha/betaR expression in 4% (2/46) of patients, moderate expression in 20% (9/46) of patients, and faint or no expression in 76% (35/46) of patients. IHC confirmed a high expression of IFN-gammaR in 52% (24/46) of patients, moderate expression in 35% (16/46) of patients, and faint or no expression in the remaining 13% (6/46) of patients. Thirty-two (69.7%) patients received adjuvant therapy. Clinicopathological survey did not demonstrate any significant correlation between IFN-alpha/betaR and IFN-gammaR expression with regard to tumor size, vascular invasion, perineural invasion, lymph node metastases, or stage of disease. Use of adjuvant therapy was associated with increased survival in patients with IFN-alpha/betaR-positive tumors compared with patients with IFN-alpha/betaR-negative tumors (24 months versus 14.7 months in log rank test, p=0.012). The expression of IFN-gammaR, however, had no impact on patient survival (20 months vs 17 months; p=0.656, log rank test).

Conclusion: IFN-alpha/betaR is associated with improved survival for patients with resectable pancreatic cancer who received adjuvant therapy.

Keywords: adjuvant therapy; interferon; interferon receptor; pancreatic cancer.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Survival of patients based on their IFN-α/β receptor expression and adjuvant therapy.
Figure 2.
Figure 2.
Expression of IFN-γ receptor did not predict response to adjuvant therapy.
Figure 3.
Figure 3.
Immunohistochemistry demonstrating moderate expression of the IFN-α/β (A) and IFN-γ receptors (B).
See this image and copyright information in PMC

References

    1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106–30. - PubMed
    1. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med. 1992;326:455–65. - PubMed
    1. Ahrendt SA, Pitt HA. Surgical management of pancreatic cancer. Oncology. 2002;16:725–34. - PubMed
    1. Saidi RF, Williams F, Ng J, Danquah G, Mittal VK, ReMine SG, et al. Interferon receptors and the caspase cascade regulate the antitumor effects of interferons on human pancreatic cancer cell lines. Am J Surg. 2006;191:358–63. - PubMed
    1. Saidi RF, Williams F, Silberberg B, ReMine SG, Jacobs MJ. Expression of interferon receptors in pancreatic cancer: identification of a novel prognostic factor. Surgery. 2006;139:743–8. - PubMed